CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.19B, above the global median of $1.15B
- PositionPrice-to-book is 0.67×, lower than 95% of its Medical Devices peers (median 3.08×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.19BUSDvs all stocks (USD)
Revenue (TTM)
2.66BUSDvs all stocks (USD)
Profit Margin
-45.57%vs Medical Devices peers
Beta
0.6920xvs all stocks
52-Week Change
-31.30%vs all stocks
Market Capitalization
1.19BUSDvs all stocks (USD)
Enterprise Value
3.98BUSDvs all stocks (USD)
Forward P/E
7.42xvs Medical Devices peers
Price to Sales (TTM)
0.4681xvs Medical Devices peers
Price to Book (MRQ)
0.6709xvs Medical Devices peers
Enterprise to Revenue
1.50xvs Medical Devices peers
Enterprise to EBITDA
8.09xvs Medical Devices peers
Gross Margin
42.56%vs Medical Devices peers
Profit Margin
-45.57%vs Medical Devices peers
Operating Margin
-4.10%vs Medical Devices peers
Return on Assets (TTM)
0.51%vs Medical Devices peers
Return on Equity (TTM)
-49.95%vs Medical Devices peers
Revenue (TTM)
2.66BUSDvs all stocks (USD)
Revenue per Share (TTM)
39.09USDUpdated Jul 19, 2026Quarterly Revenue Growth
-10.50%vs Medical Devices peers
Gross Profit (TTM)
1.20BUSDvs all stocks (USD)
EBITDA (TTM)
422.10MUSDvs all stocks (USD)
Net Income (TTM)
-1.21BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-10.54%vs Medical Devices peers
Operating Cash Flow (TTM)
6.60MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
208.58MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
2.73BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.46BUSDFY2025 · Dec 31, 2025Gross Profit
1.27BUSDFY2025 · Dec 31, 2025Operating Income
54.80MUSDvs all stocks (USD)
Pre-tax Income
-1.11BUSDFY2025 · Dec 31, 2025Income Tax Expense
24.10MUSDFY2025 · Dec 31, 2025Net Income
-1.13BUSDFY2025 · Dec 31, 2025EBIT
-924.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
488.50MUSDFY2025 · Dec 31, 2025Research & Development
186.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
746.30MUSDFY2025 · Dec 31, 2025Other Operating Expenses
97.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
183.10MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.13BUSDFY2025 · Dec 31, 2025Operating Cash Flow
-770.50MUSDFY2025 · Dec 31, 2025Free Cash Flow
-958.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
169.80MUSDFY2025 · Dec 31, 2025Interest Paid
172.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.13BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
442.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
6.30MUSDFY2025 · Dec 31, 2025Stock-based Compensation
45.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
900.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-117.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
40.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-56.30MUSDFY2025 · Dec 31, 2025Capital Expenditures
-188.20MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
-4.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-192.70MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.56BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.41BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
3.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-5.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
155.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
68.08MSharesUpdated Jul 19, 2026Float Shares
62.11MSharesUpdated Jul 19, 2026Shares Short
11.51MSharesUpdated Jul 19, 2026Short Ratio
5.87daysvs all stocks
Short % of Shares Outstanding
23.05%vs all stocks
% Held by Insiders
0.90%vs all stocks
% Held by Institutions
128.16%vs all stocks
Total Cash (MRQ)
140.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.06USDUpdated Jul 19, 2026Total Debt (MRQ)
2.87BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.55xvs Medical Devices peers
Current Ratio (MRQ)
1.43xvs Medical Devices peers
Book Value per Share (MRQ)
27.19USDUpdated Jul 19, 2026Total Assets
5.77BUSDvs all stocks (USD)
Total Current Assets
1.45BUSDFY2025 · Dec 31, 2025Total Liabilities
3.85BUSDFY2025 · Dec 31, 2025Total Non-current Assets
4.32BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.88BUSDFY2025 · Dec 31, 2025Total Current Liabilities
966.10MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
169.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
417.00MUSDFY2025 · Dec 31, 2025Inventory
577.60MUSDFY2025 · Dec 31, 2025Accounts Payable
279.40MUSDFY2025 · Dec 31, 2025Short-term Debt
207.60MUSDFY2025 · Dec 31, 2025Deferred Revenue
37.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
164.30MUSDFY2025 · Dec 31, 2025Long-term Debt
2.63BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
166.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-996.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.92BUSDvs all stocks (USD)
52-Week Low
9.92USDUpdated Jul 19, 202652-Week High
35.58USDUpdated Jul 19, 202652-Week Change
-31.30%vs all stocks
Beta
0.6920xvs all stocks
50-Day MA
13.96USDUpdated Jul 19, 2026200-Day MA
21.53USDUpdated Jul 19, 2026Avg 10-Day Volume
1.19MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.72MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-17.85USDUpdated Jul 19, 2026Other Income / Expense
-976.90MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.67×, lower than 95% of its Medical Devices peers (median 3.08×)Notable
Price-to-book: 0.67Industry median: 3.08Industry P5: 1.04Peers compared: 59.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.46
Financial Health
Altman Z-Score -0.01: distress zoneCritical
Altman Z-Score: -0.01
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.19B, above the global median of $1.15BNotable
Market cap (USD): 1,185,159,388Global Median: 1,146,734,693.424
Revenue is $2.66B, above the global median of $520.53MNotable
Revenue (USD): 2,657,200,128Global Median: 520,528,949.311
Levered free cash flow is $208.58M, above the global median of $16.24MNotable
Levered free cash flow (USD): 208,575,008Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Wondfo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiuzhitang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Lukang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tandem Diabetes Care Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Zhejiang Hangke Technology Co., Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline